# SUPRAME: what clinicians are saying

> 108 statements from 39 sources (3 podcasts, 3 videos, 33 posts), 56 of them from 9 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
- NCT ID: NCT06743126
- Registry: https://clinicaltrials.gov/study/NCT06743126
- Sponsor: Immatics US, Inc.
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: anzutresgene autoleucel (IMA203)
- Indication: previously treated, unresectable or metastatic cutaneous melanoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: 0a3613f9041f18b70fb00c03d7a922311a03ea6e570acd12d1897c4fae73659e

## Counts

- Commentary sources screened: 66
- Sources cited by verified statements: 39
- Verified statements: 108
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 56
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Speakers cited: 16
- Cited speakers with a verified identity: 10
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 9
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 9
- By role and specialty (the abstract's specialty counts):
  - 4 physician, specialty not confirmed
  - 4 physician, Medical oncology
  - 1 physician, Hematology and oncology
- Organisational or shared accounts (not counted as people): 9

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For SUPRAME, the clinicians cited see potential to change care based on earlier response activity, but comparative benefit remains unproven. One physician sees a possible option for some patients unsuitable for lifileucel, dependent on HLA matching and future approval. A physician described in the sources as presenting the trial cautions that treatment remains intensive despite avoiding surgery. Comparative safety remains uncertain, and differing descriptions of interleukin support remain unresolved.

## Question clinicians left open

What do clinicians need SUPRAME to show on progression-free survival versus investigator's choice before using IMA203 as standard care for HLA-A*02:01-positive, PD-1-refractory unresectable or metastatic cutaneous melanoma?

From findings F1 (25 statements from 8 speakers in 18 sources) and F6 (12 statements from 3 speakers in 7 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Phase 1 IMA203: what most speakers highlight in PD-1-refractory melanoma response rates
  - 25 statements from 8 speakers in 18 sources, 6 of them podcasts or videos.
  - 7 of the 8 named speakers in this finding hold this view.
  - 5 of the report's 9 cited clinicians.
- F2. IMA203 vs TIL: some clinicians value no surgery; one flags therapy intensity
  - 17 statements from 4 speakers in 8 sources, 5 of them podcasts or videos.
  - 2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags therapy intensity”.
  - 2 of the report's 9 cited clinicians.
- F3. Phase 1 IMA203 safety: where speakers split on the toxicity burden
  - 10 statements from 4 speakers in 8 sources, 5 of them podcasts or videos.
  - 4 of the 4 named speakers in this finding take a side on this question.
  - 2 of the report's 9 cited clinicians.
- F4. IMA203 access: why most speakers stress HLA matching
  - 13 statements from 5 speakers in 9 sources, 5 of them podcasts or videos.
  - 3 of the 5 named speakers in this finding hold this view.
  - 3 of the report's 9 cited clinicians.
- F5. Cell therapy: what speakers say
  - 5 statements from 1 speaker in 2 sources, all podcasts or videos.
  - 1 of the report's 9 cited clinicians.
- F6. SUPRAME: why clinicians value randomization; one frames it as TCR vs TIL
  - 12 statements from 3 speakers in 7 sources, 6 of them podcasts or videos.
  - 3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one frames it as TCR vs TIL”.
  - 3 of the report's 9 cited clinicians.
- F7. Cell therapy: what speakers say
  - 14 statements from 5 speakers in 14 sources, 3 of them podcasts or videos.
  - 4 of the report's 9 cited clinicians.
- F8. SUPRAME: what speakers say
  - 12 statements from 2 speakers in 7 sources.
  - No named clinician · accounts and unnamed speakers.
- F9. SUPRAME: what speakers say
  - 10 statements in 7 sources.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F10. PRAME-directed TCR-T: some clinicians consider broader solid-tumor use possible
  - 7 statements from 4 speakers in 5 sources, 3 of them podcasts or videos.
  - 2 of the 4 named speakers in this finding hold this view, each a confirmed clinician.
  - 4 of the report's 9 cited clinicians.

1 of the 10 findings and 5 of the 108 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 25 | 20 | 18 | 8 | 3 |
| F2 | 17 | 11 | 8 | 4 | 2 |
| F3 | 10 | 9 | 8 | 4 | 4 |
| F4 | 13 | 12 | 9 | 5 | 3 |
| F5 | 5 | 3 | 2 | 1 | 2 |
| F6 | 12 | 9 | 7 | 3 | 3 |
| F7 | 14 | 14 | 14 | 5 | 2 |
| F8 | 12 | 9 | 7 | 2 | 3 |
| F9 | 10 | 8 | 7 | 0 | 4 |
| F10 | 7 | 5 | 5 | 4 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 16 | 0 | 0 | 3 | 6 | 25 | 2 | 12 posts and articles, 6 podcasts and video |
| F2 | 1 | 2 | 0 | 13 | 1 | 17 | 1 | 3 posts and articles, 5 podcasts and video |
| F3 | 1 | 0 | 1 | 4 | 4 | 10 | 2 | 3 posts and articles, 5 podcasts and video |
| F4 | 6 | 2 | 0 | 3 | 2 | 13 | 2 | 4 posts and articles, 5 podcasts and video |
| F5 | 3 | 0 | 2 | 0 | 0 | 6 | 0 | 2 podcasts and video |
| F6 | 6 | 0 | 0 | 0 | 6 | 12 | 0 | 1 post or article, 6 podcasts and video |
| F7 | 11 | 0 | 2 | 0 | 1 | 14 | 0 | 11 posts and articles, 3 podcasts and video |
| F8 | 4 | 4 | 0 | 0 | 4 | 16 | 2 | 7 posts and articles |
| F9 | 5 | 1 | 0 | 4 | 0 | 16 | 8 | 7 posts and articles |
| F10 | 5 | 0 | 1 | 1 | 0 | 7 | 0 | 2 posts and articles, 3 podcasts and video |

### Trial dimensions

- Primary endpoint: Progression-free survival assessed by BICR: F1 (1 shared claims), F6 (2 shared claims), F8 (5 shared claims)
- Secondary endpoints: F1 (3 shared claims), F2 (1 shared claims), F3 (1 shared claims), F6 (1 shared claims), F9 (2 shared claims)
- Population and setting: F1 (2 shared claims), F3 (1 shared claims), F4 (10 shared claims), F5 (3 shared claims), F6 (3 shared claims), F7 (1 shared claims), F8 (1 shared claims)
- The comparison: F1 (3 shared claims), F2 (14 shared claims), F3 (5 shared claims), F4 (2 shared claims), F6 (3 shared claims), F9 (1 shared claims)
- Safety and tolerability: F1 (4 shared claims), F2 (5 shared claims), F3 (8 shared claims), F5 (1 shared claims), F9 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F4 (1 shared claims), F6 (7 shared claims), F7 (2 shared claims), F8 (9 shared claims)

## Abbreviations

- BICR: blinded independent central review
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Physician, US, identity checked against NPI · podcast · Jan 2026 (finding F1): A physician identifies the SUPRAME trial as one of the trials generating the most excitement.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 108 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 9 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 10 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 39 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 9 of the 16 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival assessed by BICR | discussed | 7 | 7 |
| Secondary endpoints | discussed | 6 | 5 |
| Population and setting | discussed | 17 | 11 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 21 | 8 |
| Safety and tolerability | discussed | 11 | 9 |
| Design and conduct | discussed | 18 | 14 |
| HLA and PRAME work-up | discussed | 11 | 7 |
| Sequencing, progression monitoring and trial referral | discussed | 12 | 8 |
| Manufacturing, administration and service readiness | discussed | 13 | 8 |
| Earlier IMA203 phase 1/1b evidence and its relevance to SUPRAME expectations | discussed | 18 | 17 |
| Secondary-source forecasts and competing-development benchmarks | discussed | 16 | 12 |
| Potential PRAME platform beyond melanoma | discussed | 6 | 5 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 53 statements · 49%** | | | |
| YouTube | 22 | 3 | 4 |
| Podcasts | 31 | 3 | 3 |
| **Posts · 55 statements · 51%** | | | |
| X threads | 46 | 24 | 47 |
| LinkedIn posts | 5 | 5 | 5 |
| Bluesky threads | 4 | 4 | 7 |

- Screened window: 2024-10-10 to 2026-10-30
- Cited window: 2024-10-11 to 2026-10-30
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
- Registry: NCT06743126 (https://clinicaltrials.gov/study/NCT06743126)
- Study IDs: IMA203-301
- Sponsor: Immatics US, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 450 (estimated)
- Start: 2025-01-14 (actual)
- Primary completion: 2028-01 (estimated)
- Primary endpoint: Progression-free survival assessed by BICR (up to 5 years post first treatment of last patient)
- Intervention: IMA203 (biological)
- Intervention: nivolumab plus relatlimab (biological)
- Intervention: lifileucel (biological)
- Intervention: nivolumab (biological)
- Intervention: pembrolizumab (biological)
- Intervention: ipilimumab (biological)
- Intervention: Dacarbazine (drug)
- Intervention: temozolomide (drug)
- Intervention: paclitaxel (drug)
- Intervention: paclitaxel plus carboplatin (drug)
- Intervention: Albumin-Bound Paclitaxel (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on enthusiasm for the investigational cell therapy and enrollment in its phase three trial; a remark on the treatment comparison in previously treated unresectable or metastatic cutaneous melanoma; a view on anticipated local trial access as another treatment option for advanced melanoma; a view on earlier tolerability evidence for investigational T-cell therapy in previously treated advanced melanoma.
- 2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 3 passages in 3 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 9 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selected public discussion, not a representative HCP survey. Repeated statements and cross-platform posts cannot be counted as independent clinician agreement.
- Discussion without recognized trial or drug wording may be absent. Several possible passages were not fully assessed, and some earlier discussion and media relays are not represented; additional or historically earlier views may therefore be missing.
- Coverage of alternative investigational choices and account-level preferences is incomplete. The HLA-typing point and uveal-enrollment question alone do not describe those choices or preferences.
- No full SUPRAME protocol or exact-trial publication was available in the reviewed material to reconcile secondary amendment descriptions. Exact regulatory labeling for IMA203 and nivolumab plus relatlimab was also incomplete, limiting independent confirmation of authorized-use descriptions.
- The cited efficacy and safety observations concern earlier IMA203 studies, not randomized SUPRAME outcomes. Accounts describing a cutaneous-melanoma cohort, heavily refractory advanced melanoma or metastatic melanoma should not be pooled as if they described one population.
- Earlier accounts give different prior-treatment figures, response wording and IL-2 descriptions. Those differences remain unresolved rather than being silently harmonized, and the episode's unattributed IL-2 wording does not establish disagreement between named speakers.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Relayed company announcements, analyst notes and a research note's interpretation of a KOL survey are not direct individual HCP testimony. Probabilities, comparative labels and survival benchmarks remain those sources' assessments.
- Activation accounts, eligibility descriptions and projected readout or filing dates retain their original timing. They do not establish present site availability, a current complete eligibility checklist or completed regulatory milestones.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition
  - Routine maintenance: 2 fixes (names, counts, text):
    - 2026-11-20 UTC: The trial's name is spelled as its investigators write it, “SUPRAME” (NCT06743126), outside quotations (was “SURPRAME”).
    - 2026-11-20 UTC: An editorial bracket follows a transcription-garbled trial name in quotations: “SURPRAME [SUPRAME]”.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 108 verified statements · 56 from 9 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (10 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/suprame-nct06743126
- Agents: POST https://www.erudio.com/api/orders with {"report": "suprame-nct06743126", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=suprame-nct06743126

## Cite

Erudio Health. SUPRAME (NCT06743126): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/suprame-nct06743126

## Questions

### How much does the SUPRAME report cost?

One edition costs $750 (Focused · 108 verified statements · 56 from 9 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the SUPRAME report cover?

108 statements from 39 sources (3 podcasts, 3 videos, 33 posts), 56 of them from 9 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the SUPRAME report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "suprame-nct06743126" }) previews it and create_order({ "report": "suprame-nct06743126", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the SUPRAME report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/suprame-nct06743126.json
- Markdown: https://www.erudio.com/reports/suprame-nct06743126.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/suprame-nct06743126/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "suprame-nct06743126"}`
